Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):372–375. doi: 10.1038/bjc.1990.300

Intratumoral induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine.

H Minagawa 1, H Kobayashi 1, H Yoshida 1, M Teranishi 1, A Morikawa 1, S Abe 1, H Oshima 1, D I Mizuno 1
PMCID: PMC1971444  PMID: 2206945

Abstract

Intratumoral induction of tumour necrosis factor (TNF) by administration of Bordetella pertussis vaccine (BPV) as compared with that by the agent OK-432 was investigated in mice. Two hours after such administration tumour tissues tested were resected from the mice, homogenised, and the TNF activities in the homogenate were assayed using a L-929 fibroblast assay. Intravenous injection of BPV into mice bearing the MM46 carcinoma resulted in a greater concentration of TNF in the tumour homogenate than in the serum. With OK-432, however, there was a greater concentration of TNF in the serum than in the tumour homogenates. A high level of intratumoral TNF induction by BPV was also observed in mice bearing Meth A fibrosarcoma or Lewis lung carcinoma. The therapeutic effect against the Meth A fibrosarcoma was in parallel with the intratumoral TNF activity. Intratumoral TNF activity is therefore believed to be a good index of therapeutic effect.

Full text

PDF
372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gatanaga T., Noguchi K., Tanabe Y., Inagawa H., Soma G., Mizuno D. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo. J Biol Response Mod. 1989 Jun;8(3):278–286. [PubMed] [Google Scholar]
  3. Gatanaga T., Takahashi K., Yamazaki M., Mizuno D., Abe S. Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immuno-therapeutic agents against murine tumors. Jpn J Cancer Res. 1985 Jul;76(7):631–636. [PubMed] [Google Scholar]
  4. Kato M., Ishiwata D., Kakehi R., Oshima N., Soma G., Mizuno D. [Partial response of lung metastases from a renal cancer treated with endogenous tumor necrosis factor]. Gan To Kagaku Ryoho. 1987 Jul;14(7):2378–2380. [PubMed] [Google Scholar]
  5. Kato M., Kakehi R., Soma G. I., Gatanaga T., Mizuno D. Anti-tumour therapy by induction of endogenous tumour necrosis factor. Lancet. 1985 Aug 3;2(8449):270–270. doi: 10.1016/s0140-6736(85)90312-5. [DOI] [PubMed] [Google Scholar]
  6. Minagawa H., Kakamu Y., Yoshida H., Tomita F., Oshima H., Mizuno D. Endogenous tumor necrosis factor induction with Bordetella pertussis vaccine as a triggering agent and its therapeutic effect on MM46 carcinoma-bearing mice. Jpn J Cancer Res. 1988 Mar;79(3):384–389. doi: 10.1111/j.1349-7006.1988.tb01602.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  8. Satoh M., Inagawa H., Minagawa H., Kajikawa T., Oshima H., Abe S., Yamazaki M., Mizuno D. Endogenous production of TNF in mice long after BCG sensitization. J Biol Response Mod. 1986 Apr;5(2):117–123. [PubMed] [Google Scholar]
  9. Satoh M., Inagawa H., Minagawa H., Kajikawa T., Oshima H., Abe S., Yamazaki M., Mizuno D. Endogenous production of TNF in mice with immune complex as a primer. J Biol Response Mod. 1986 Apr;5(2):140–147. [PubMed] [Google Scholar]
  10. Satoh M., Shimada Y., Inagawa H., Minagawa H., Kajikawa T., Oshima H., Abe S., Yamazaki M., Mizuno D. Priming effect of interferons and interleukin 2 on endogenous production of tumor necrosis factor in mice. Jpn J Cancer Res. 1986 Apr;77(4):342–344. [PubMed] [Google Scholar]
  11. Springer T., Galfré G., Secher D. S., Milstein C. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol. 1979 Apr;9(4):301–306. doi: 10.1002/eji.1830090410. [DOI] [PubMed] [Google Scholar]
  12. TREFFERS H. P. The linear representation of dosage-response curves in microbial-antibiotic assays. J Bacteriol. 1956 Jul;72(1):108–114. doi: 10.1128/jb.72.1.108-114.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Takahashi K., Yamazaki M., Abe S. Local induction of a tumor necrosis factor (TNF)-like cytotoxic factor in murine tissues with tumorous and nontumorous inflammation after systemic administration of antitumor polysaccharides. J Pharmacobiodyn. 1988 Jul;11(7):472–478. doi: 10.1248/bpb1978.11.472. [DOI] [PubMed] [Google Scholar]
  14. Uchida A., Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer. 1980 Feb;45(3):476–483. doi: 10.1002/1097-0142(19800201)45:3<476::aid-cncr2820450311>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES